Amgen/Cytokinetics Phase III Heart Failure Data Are Below Expectations

Omecamtiv Met Primary, Missed Key Secondary Endpoints

 
• By Mandy Jackson

Analysts considered the Phase III GALACTIC-HF study of omecamtiv mecarbil a failure but some anticipated that detailed data to be presented next month could at least partially redeem the drug.

Paper heart
Omecamtiv reduced a composite of hospitalizations and deaths with no significant impact on deaths alone • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas